Skinny-Labeling in Hatch-Waxman Litigations: The Law in Flux?
The Hatch-Waxman Act was originally designed to spur pharmaceutical innovation and increase consumer access to affordable drugs. However, given the complex nature of this law, several regulatory and patent issues have come to light, including the use of carved-out labels, or “skinny labels,” by generic drug manufacturers. However, skinny labels could potentially induce infringement. Thus, the need for pharmaceutical companies to keep track of emerging issues and recent court rulings surrounding this evolving legal climate remains paramount. Listen as a panel of key thought leaders and practitioners organized by The Knowledge Group provide the audience with an in-depth look at [...]